RESUMO
Gastric cancer is a world health problem and depicts the fourth leading mortality cause from malignancy in Mexico. Causation of gastric cancer is not only due to the combined effects of environmental factors and genetic variants. Recent molecular studies have transgressed a number of genes involved in gastric carcinogenesis. The aim of this review is to understand the recent basics of gene expression in the development of the process of gastric carcinogenesis. Genetic variants, polymorphisms, desoxyribonucleic acid methylation, and genes involved in mediating inflammation have been associated with the development of gastric carcinogenesis. Recently, these genes (interleukin 10, Il-17, mucin 1, ß-catenin, CDX1, SMAD4, SERPINE1, hypoxia-inducible factor 1 subunit alpha, GSK3ß, CDH17, matrix metalloproteinase 7, RUNX3, RASSF1A, TFF1, HAI-2, and COX-2) have been studied in association with oncogenic activation or inactivation of tumor suppressor genes. All these mechanisms have been investigated to elucidate the process of gastric carcinogenesis, as well as their potential use as biomarkers and/or molecular targets to treatment of disease.
RESUMO
OBJECTIVE: Monogenic congenital cataract is one of the most genetically heterogeneous ocular conditions with almost 30 different genes involved in its etiology. In adult patients, genotype-phenotype correlations are troubled by eye surgery during infancy and/or long-term ocular complications. Here, we describe the molecular diagnosis of GALK1 deficiency as the cause of autosomal recessive congenital cataract in a family from Costa Rica. METHODS: Four affected siblings were included in the study. All of them underwent eye surgery during the first decade but medical records were not available. Congenital cataract was diagnosed by report. Molecular analysis included genome wide homozygosity mapping using a 250K SNP Affymetrix microarray followed by PCR amplification and direct nucleotide sequencing of candidate gene. RESULTS: Genome wide homozygosity mapping revealed a 6Mb region of homozygosity shared by two affected siblings at 17q25. The GALK1 gene was included in this interval and direct sequencing of this gene revealed a homozygous c.1144C>T mutation (p.Q382) in all four affected subjects. CONCLUSIONS: This work demonstrates the utility of homozygosity mapping in the retrospective diagnosis of a family with congenital cataracts in which ocular surgery at early age, the lack of medical records, and the presence of long term eye complications, impeded a clear clinical diagnosis during the initial phases of evaluation.
Assuntos
Catarata/congênito , Catarata/genética , Galactoquinase/genética , Genes Recessivos , Mutação , Idoso , Mapeamento Cromossômico/métodos , Análise Mutacional de DNA/métodos , Olho , Feminino , Galactoquinase/deficiência , Ligação Genética/genética , Estudo de Associação Genômica Ampla/métodos , Homozigoto , Humanos , Masculino , Pessoa de Meia-Idade , Patologia Molecular/métodos , Linhagem , Estudos Retrospectivos , IrmãosRESUMO
En los últimos años ha cobrado importancia el estudio de las alteraciones epigenéticas en el desarrollo del cáncer. La metilación del ácido desoxirribonucleico es el cambio epigenético más frecuente e importante hasta ahora estudiado, y tiene un importante papel en la regulación transcripcional de genes. Recientemente se ha observado que existen patrones de metilación anormales en muchos tipos de cánceres, incluyendo el cáncer de tiroides, los cuales conducen a la inactivación de genes supresores de tumores y a la inestabilidad del genoma. La metilación de genes específicos, tales como, el cotransportador de yodo/sodio, la tiroglobulina y el receptor de la hormona estimulante del tiroides en el cáncer diferenciado de tiroides, es una de las causas de fallo en el tratamiento de los pacientes con esta enfermedad. Se ha iniciado el tratamiento con agentes desmetilantes en los pacientes con cáncer de tiroides que presentan una alteración genética por metilación, a fin de corregir estas alteraciones, restablecer la función, y con ello, la posibilidad de que el tratamiento sea efectivo(AU)
In past years the study of epigenetic alterations in the cancer development becomes significance. The methylation of desoxyribonucleic acid is the more frequent and important epigenetic change until now studied and play a significant role in the transcription regulation of genes. Recently it was noted the existence of abnormal methylation patterns in many types of cancer, including the thyroid one, which leading to inactivation of tumor suppressors genes and to genome instability. The methylation of specific genes such as the co-transporter of iodine/sodium, the thyroglobulin and the receptor of thyroid stimulant hormone (TSH) in the thyroid differentiated cancer, is one of the failure cause in treatment of patients presenting this disease. In patients with thyroid cancer it has been initiated a treatment with demethylation agents in patients with abovementioned cancer with a genetic alteration due to methylation to correct these alterations, to restore the function and thus the possibility of a effective treatment(AU)
Assuntos
Humanos , Neoplasias da Glândula Tireoide , Metilação de DNA , Epigênese GenéticaRESUMO
En los últimos años ha cobrado importancia el estudio de las alteraciones epigenéticas en el desarrollo del cáncer. La metilación del ácido desoxirribonucleico es el cambio epigenético más frecuente e importante hasta ahora estudiado, y tiene un importante papel en la regulación transcripcional de genes. Recientemente se ha observado que existen patrones de metilación anormales en muchos tipos de cánceres, incluyendo el cáncer de tiroides, los cuales conducen a la inactivación de genes supresores de tumores y a la inestabilidad del genoma. La metilación de genes específicos, tales como, el cotransportador de yodo/sodio, la tiroglobulina y el receptor de la hormona estimulante del tiroides en el cáncer diferenciado de tiroides, es una de las causas de fallo en el tratamiento de los pacientes con esta enfermedad. Se ha iniciado el tratamiento con agentes desmetilantes en los pacientes con cáncer de tiroides que presentan una alteración genética por metilación, a fin de corregir estas alteraciones, restablecer la función, y con ello, la posibilidad de que el tratamiento sea efectivo(AU)
In past years the study of epigenetic alterations in the cancer development becomes significance. The methylation of desoxyribonucleic acid is the more frequent and important epigenetic change until now studied and play a significant role in the transcription regulation of genes. Recently it was noted the existence of abnormal methylation patterns in many types of cancer, including the thyroid one, which leading to inactivation of tumor suppressors genes and to genome instability. The methylation of specific genes such as the co-transporter of iodine/sodium, the thyroglobulin and the receptor of thyroid stimulant hormone (TSH) in the thyroid differentiated cancer, is one of the failure cause in treatment of patients presenting this disease. In patients with thyroid cancer it has been initiated a treatment with demethylation agents in patients with abovementioned cancer with a genetic alteration due to methylation to correct these alterations, to restore the function and thus the possibility of a effective treatment(AU)